Pharma firms lean on US trademark law to halt weight loss drug counterfeits
Drug companies are increasingly turning to the Lanham Act in the US to stop the distribution of GLP-1 weight loss medications by compounding pharmacies. Industry leaders say compounded drugs sold as...To view the full article, register now.
Already a subscriber? Click here to view full article